THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era Tuesday, March 10, 2026

COMPOUND WATCH

BPC-157 [Phase 2 — first human RCT now recruiting] [Animal — extensive rodent data] The number that matters: 14. That's how many humans appeared in the entire published BPC-157 literature before this month — a 2-person IV infusion pilot, a 12-patient retrospective case series with no control group, and a Phase I registered in 2015 and quietly canceled in 2016. That's what hundreds of thousands of people have been injecting based on. Now there's a real trial: NCT07437547 — Phase 2, acute hamstring muscle strain, recruiting since February 2. It won't answer your gut healing or systemic inflammation questions. But it will produce the first controlled human safety and dosing data this compound has ever had. Evidence grade moves from [Animal/Anecdotal] to [Phase 2 — limited indication]. File under: finally.

GLP-1 sex differences — first neuroanatomical map [Animal — murine, high translational confidence] If you're male and your GLP-1 results are running below trial averages, this is the first mechanistic explanation for why. Mount Sinai published the first sex-specific atlas of GLP-1 expression across 25 brain regions today (Brain Medicine, open access, DOI: 10.61373/bm026a.0006), using single-transcript resolution. Key findings: females show stronger appetite suppression and weight loss effects; males show distinct GLP-1 expression in the olfactory bulb, potentially linked to olfactory-driven insulin signaling. The preproglucagon expression pattern is conserved in nonhuman primates — this isn't just a mouse story. It doesn't change your protocol today, but it's the mechanistic foundation for sex-stratified dosing research that's coming. If you're a male on tirzepatide or semaglutide and you're underperforming the trial averages, this paper is the most important thing published this month.

Tirzepatide vs. Semaglutide — ION eye risk [Large observational — 30M+ FDA adverse event reports] A new British Journal of Ophthalmology study found Wegovy (2.4mg injectable semaglutide) is ~5x more likely to cause ischemic optic neuropathy ("eye stroke") than Ozempic. Tirzepatide: no significant ION association. Rybelsus (oral semaglutide tablet): zero reported ION cases. Proposed mechanism — not confirmed — is that high-dose injectable semaglutide may reduce optic nerve blood flow via fluid loss and nocturnal hypotension; the oral route's slower absorption may avoid the peak concentration spikes that drive this. Males are 3x more likely than females to appear in ION reports. One-sentence answer for your circle: Wegovy-dose injectable semaglutide is the signal; tirzepatide is not implicated; oral semaglutide has zero reported cases. If you're male on injectable Wegovy-dose and notice any visual disturbance, that's an ER visit, not a wait-and-see.

Petrelintide (Roche, amylin analog) [Phase 2] ZUPREME-1 (n=493, five active dose groups): up to 10.7% mean weight loss at 42 weeks vs. 1.7% placebo. The headline isn't the number — it's the tolerability. Dr. Donna H. Ryan at Pennington Biomedical: "The tolerability appears to be the best we've yet to observe." No notable GI adverse events beyond fatigue across all five groups. 10.7% is well below tirzepatide's 22%+ ceiling, but a GI-silent mechanism matters enormously for patients who can't tolerate GLP-1 nausea. ZUPREME-2 (T2D + obesity cohort) topline expected H2 2026.

The markup cascade — precision version: Raw semaglutide API: ~$0.01 per 2.4mg dose (~$39,866/kg). Fully formulated — excipients, manufacturing, transport, 30% manufacturer margin, 27% tax: ~$0.12–$0.54 per dose, or $28–$140 per person-year once patents expire (India, China, Canada, Brazil: April 2026; ~160 countries by end of 2026). U.S. branded Wegovy: ~$10,000/year. Critical caveat: pen injector device cost alone can be 8–68x the drug cost — the $28/year figure is a manufacturing floor, not a pharmacy shelf price. Real-world Indian generics will likely land at $200–$400/year once device costs are included. Still a 96–98% discount. Still a hostage situation.

VENDOR SIGNAL

Peptide Sciences — [Flagged / Winding Down] The Frier Levitt legal analysis published today cites that Peptide Sciences — one of the most prominent and longest-standing U.S. research peptide vendors — "has announced it will wind down operations and will discontinue the sale of research peptides." Frier Levitt frames this explicitly as pre-enforcement compliance: "for the unregulated market, this may signal a narrowing window before regulatory and enforcement pressure intensifies."

Important caveats: No independent confirmation exists beyond this citation. No official statement from Peptide Sciences has been verified. No timeline published. Verify directly at peptidesciences.com before acting. Do not panic-order. Do not assume existing COAs are invalid. Do not place large orders with a vendor that may be in wind-down mode without understanding what happens to your order if they close mid-fulfillment.

Practical impact: If confirmed, this is the largest research peptide vendor exit in U.S. market history. Demand redistributes to QSC, Amino Asylum, and remaining active vendors. Watch for price increases and COA quality pressure as those vendors absorb new customers. Finnrick ratings may shift within 2–4 weeks as the community stress-tests alternatives.

No compounder pricing updates today (no fresh data for Empower, Olympia, Marek Health, or Defy Medical confirmed in today's sources). Last confirmed compounder pricing for compounded tirzepatide: $200–$500/month range. If you're tracking specific compounder prices, check directly — the Peptide Sciences story may already be driving demand redistribution that affects pricing.

No new Finnrick rating changes or failed HPLC/Janoshik tests confirmed today. Check finnrick.com before placing any order this week — the landscape is actively shifting. Reminder: 15–20% of supplier COAs show discrepancies when independently verified.

The 30 FDA warning letters from March 3 remain the most recent confirmed enforcement action. No new warning letters, raids, or criminal prosecutions confirmed today.

TRIAL TRACKER

[NCT07437547] BPC-157 — Acute Hamstring Muscle Strain | Phase 2 | Recruiting | Started Feb 2, 2026 First Phase 2 RCT for BPC-157 in human history. Narrow indication — won't answer gut healing or systemic inflammation questions — but will produce the first controlled human purity, dosing, and safety data this compound has ever had. If it reads positive, expect follow-on trials. If it shows unexpected safety signals, that's information the community has never had before.

[NCT pending] Veru PLATEAU — Enobosarm 3mg + Semaglutide, Lean Mass Preservation | Phase IIb | First Patient Enrolled March 10, 2026 This is a same-day milestone. Phase IIb PLATEAU (n=~200, aged ≥65, BMI ≥35, starting semaglutide) enrolled its first patient today. Tests oral enobosarm (SARM, 3mg) added to semaglutide to address weight loss plateau and preserve lean mass, physical function, and bone mineral density. Primary endpoint: % change in total body weight at 68 weeks. Interim DXA analysis (lean/fat mass breakdown) at 34 weeks — Q1 2027. PI: Steven Heymsfield, Pennington Biomedical. Why it matters: lean mass preservation is the most clinically important unanswered question for anyone on a GLP-1 protocol, especially over 50. If the Q1 2027 interim reads positive, the enobosarm + GLP-1 combination moves from community anecdote to Phase 2 evidence.

[NCT07357415] Retatrutide Phase 3 — Obesity Without T2D | Phase 3 | Recruiting | Started Jan 24, 2026 Retatrutide posted 24.2% weight loss at 48 weeks in Phase 2 — the highest number ever recorded for a weight loss drug at that point. Phase 3 is now enrolling. If it replicates, retatrutide becomes the new ceiling for the class and the benchmark against which every compounded peptide protocol gets measured.

THE ODDS

(Source: Polymarket — volume figures reflect contracts traded as of March 10, 2026. Higher volume = more reliable probability estimate.)

Inflation above 3% in 2026: 80% probability ($114,762 volume — thinner signal, directionally useful) The most underappreciated number for your peptide budget. Compounding pharmacy costs are labor- and material-intensive — when inflation runs hot, the $200–$500/month compounder price for tirzepatide drifts higher. Chinese API prices are denominated in yuan and largely insulated from U.S. service-sector inflation. Structural implication: the gray-market cost advantage widens as compounder prices rise. If you're already price-sensitive, this is a 6-month argument for sourcing decisions.

Recession by end of 2026: 32% probability ($515,627 volume — real money, reliable signal) Below the threshold where discretionary health spending compresses. Rule of thumb (no formal study, community heuristic): above ~40% recession odds, $200–$500/month out-of-pocket peptide spending starts to contract and gray-market sourcing increases as people trade down to QSC and SRY. At 32%, the more likely dynamic is continued compounding market growth. But if odds drift above 40% in the next 60 days, watch for increased gray-market order volumes and softening compounder demand. Check back monthly.

No Fed rate cuts in 2026: 23% probability ($1,840,094 volume — highest liquidity of any signal today, most reliable) The most liquid prediction market signal today. 77% probability of at least one rate cut means borrowing costs for compounding pharmacy buildout and peptide startup capital stay manageable. More directly: rate cuts reduce the cost pressure on small 503A pharmacies that are carrying inventory debt. If the no-cut scenario materializes (23%), expect continued consolidation pressure on smaller compounders — which concentrates the market further toward the 72 remaining registered 503B facilities.

Tariff dividend by March 31: 2% probability ($135,479 volume) Near-zero probability of tariff relief — but tariffs on Chinese goods are already in place. Chinese direct vendors (QSC, SRY, GYC) are operating under existing tariff pressure. With Peptide Sciences potentially exiting, more sourcing pressure shifts toward Chinese direct vendors, increasing your tariff exposure. No new escalation signal today, but baseline risk remains: a 25% tariff on Chinese goods could raise gray-market peptide costs 15–30%. Stock accordingly if you're relying on Chinese direct supply.

SIGNAL VS. NOISE

SIGNAL: BPC-157 Phase 2 trial recruiting [NCT07437547] First controlled human trial in the compound's history. Evidence grade moves from [Animal/Anecdotal] to [Phase 2 — limited indication]. The prior evidence base: 14 humans total. That number is now growing.

SIGNAL: Mount Sinai GLP-1 sex-specific brain atlas [Animal — high translational confidence] First mechanistic neuroanatomical explanation for why women lose more weight on GLP-1s than men. Preproglucagon expression pattern conserved in nonhuman primates. Directly relevant to any male reader underperforming trial averages.

SIGNAL: GLP-1 addiction data — BMJ, 606,434 veterans [Large observational] GLP-1 users vs. SGLT-2 inhibitor users: 25–50% lower risk of overdose, drug-related hospitalization, and death in those with prior SUD history; overdoses ~39% less common; SUD-related deaths ~50% lower. Effect consistent across alcohol, nicotine, cannabis, cocaine, and opioids. Methodological note: comparison group is SGLT-2 inhibitor users, not untreated controls — meaning the effect size is conservative. If compared to no medication, the GLP-1 advantage would likely be larger. Covered by NPR. Moves from "interesting anecdote" to "serious clinical hypothesis requiring RCT confirmation."

SIGNAL: Peptide Sciences wind-down [Regulatory/Market] Largest research peptide vendor exit in U.S. market history, if confirmed. Source is a credible healthcare law firm, not a Reddit rumor. Unconfirmed — but the framing (pre-enforcement compliance) is the interpretation to take seriously.

SIGNAL: Wegovy ION risk — 5x vs. Ozempic, zero for oral [30M+ adverse event reports] Dose-route-risk differentiation is new and clinically important. Not a reason to panic off injectable semaglutide, but a reason to understand what you're trading off at higher doses.

NOISE: RFK Jr. peptide reclassification "within a couple of weeks" He said it February 27. The window has elapsed. No Federal Register notice. No formal FDA action. No internal communication to FDA staff (per Politico, March 3). HHS has not responded to press inquiries. The Frier Levitt analysis confirms: still a podcast announcement, not a regulatory action. Don't make sourcing decisions based on a promise that's already missed its own deadline.

NOISE: UBT251 "19.7% weight loss" headlines Real data, but China Phase 2, n=205, 24 weeks. Every promising obesity drug has looked spectacular in early Chinese trials. The global Phase 2 (~330 participants, results 2027) is what matters. File as "watch closely," not "the next tirzepatide."

REGULATORY RADAR

The regulatory picture today is defined by what hasn't happened.

RFK Jr. timeline: expired without action. The "couple of weeks" cited on Joe Rogan (February 27) has passed. No Federal Register notice. No reclassification of any Category 2 peptides. At least one FDA employee whose portfolio includes compounded drugs reported "no internal communication about what is coming" (per Politico, March 3). Court filings in Evexias Med. Ctrs. v. FDA (N.D. Tex.) reflect FDA's own representation that a final rule on Ipamorelin, CJC-1295, AOD-9604, and Thymosin Alpha-1 is expected — but "expected in a court filing" and "imminent" are different things.

What reclassification would actually mean if it happens: Category 1 status doesn't mean OTC. It means compounding pharmacies with valid prescriptions, FDA-inspected API suppliers, and COA documentation could legally compound these peptides. It does not legalize the research chemical gray market. Peptide Sciences' reported wind-down fits the pre-enforcement pattern exactly.

Hims-Novo deal context: Novo has now filed 132+ lawsuits across 40 states and secured 44+ permanent injunctions against compounding pharmacies and telehealth clinics. The Hims deal — Hims abandons compounded GLP-1 promotion, becomes an authorized Novo distributor — is the template: compliant telehealth channels survive, compounding competitors get litigated out. The mass-market compounded GLP-1 era is structurally ending. The question is timeline, not direction.

Orforglipron PDUFA: April 10, 2026. Lilly's oral non-peptide GLP-1 RA. ~$1.5B inventory ready; Lilly says it can launch ~1 week post-approval. Key differentiator vs. oral Wegovy: no food/beverage timing restrictions. If approved for both obesity and T2D, competitive pressure on compounders intensifies significantly.

WHAT TO WATCH

April 10 — Orforglipron PDUFA. If approved, Lilly launches within ~1 week. Watch for immediate impact on compounded tirzepatide demand and compounder pricing. Dual obesity + T2D approval would be the more disruptive scenario.

Q1 2027 — Veru PLATEAU interim DXA analysis. Lean/fat mass breakdown at 34 weeks for the enobosarm + semaglutide combination (n=~200, aged ≥65). This is the lean mass preservation data point the community has been waiting for. If positive, the SARM + GLP-1 protocol gets its first controlled human evidence.

H2 2026 — ZUPREME-2 topline (petrelintide in T2D + obesity). If tolerability holds and efficacy is comparable to ZUPREME-1, the amylin analog class becomes a serious pipeline story for GLP-1 intolerant patients.

2027 — UBT251 global Phase 2 results (~330 participants). The 19.7% at 24 weeks needs global replication. Don't restructure your protocol around a China Phase 2 headline.

This week: Verify Peptide Sciences status directly at peptidesciences.com before placing any order. Check finnrick.com for vendor rating changes — ratings may update faster than any newsletter can track.

Recession odds above 40% = action threshold. Currently 32% on Polymarket. If odds drift above 40% in the next 60 days, expect gray-market order volumes to increase and compounder demand to soften. Check monthly.

The single most important number in today's issue: 14. That's how many humans had BPC-157 data in the published literature before this month — a 2-person IV infusion pilot, a 12-patient retrospective case series with no control group, and a Phase I that was quietly canceled in 2016. The Phase 2 trial now recruiting will eventually make that number larger. Everything you've read about BPC-157 until now was built on 14 people and a lot of rats.

Reply to this email with what you're watching, what you're sourcing, or what I got wrong. This newsletter gets better with your feedback.

Stay curious, stay skeptical. — The Dose

Like what you're reading? Upgrade to Premium for early-access signals, weekly deep-dives, and the full 12-month archive. Founding members: $5/month.